GLP-1s Keep Surprising Us: New Signals on Asthma, the Heart, and a Strange Ear Problem

Three 2025 papers, taken together, sketch the current state of play. One uses machine learning to ask which asthma patients on GLP-1s see fewer attacks. One maps the molecular fingerprints these drugs leave on the heart and vessels. And one — a small, sober case series from a German otolaryngology clinic — describes a side effect that, until last year, didn't appear in the GLP-1 conversation at all. None of these is the final word. All of them widen the frame.

Using a machine-learning method called high-dimensional iterative causal forest on MarketScan claims data from 2016–2020, a research team compared new GLP-1 users with new sulfonylurea users among patients with documented asthma. In the overall cohort, GLP-1 use was associated with a modest absolute reduction in acute asthma exacerbations — hospital admissions or ED visits — over six months. The benefit was concentrated in a specific subgroup: patients with two or more systemic-steroid fills in the lookback window, a marker of harder-to-control disease.

That's a meaningful nuance. The drugs didn't appear to do much for low-severity asthma in this analysis, but in the steroid-heavy subgroup the effect size was several times larger than the population average. This is hypothesis-generating, not prescriptive — it's a claims-database analysis, not a randomized trial — and it tells you nothing about causality at the airway level. But it's the kind of signal that earns a properly designed trial, which is probably what comes next.

The cardiovascular upside is the most established part of the GLP-1 portfolio, and a 2025 review in the International Journal of Molecular Sciences tries to explain why at a mechanistic level. Pooling 131 publications, the authors argue that GLP-1 receptor agonists and DPP-4 inhibitors reduce major adverse cardiovascular events through a cluster of effects: dampened oxidative stress, lower vascular inflammation, better endothelial function, improved mitochondrial performance, and cleaner lipid handling.

For a non-clinician reader, the practical translation is this. The cardioprotective effect doesn't appear to be a side benefit of weight loss alone — it looks like the drugs are doing distinct work on the vessel wall and the myocardium. That's consistent with the outcome trials that drove the cardiology label expansions, and it's why endocrinologists and cardiologists are increasingly thinking about these agents in patients who don't need a single additional pound shed, but do carry vascular risk.

Worth keeping the rating honest: a narrative review aggregates mechanism, not new outcomes. The hard cardiovascular endpoints come from earlier randomized trials. What this review adds is a coherent biological story for why those trials read out the way they did.

Then there's the surprise. A single otolaryngology clinic in Germany published a retrospective case series of seven adults who developed patulous Eustachian tube — a condition where the tube connecting the middle ear to the back of the throat fails to stay closed at rest — after losing 8.2% to 18.7% of body weight on semaglutide or tirzepatide. The symptoms are unmistakable once you've heard them described: autophony (your own voice booming in your head), aural fullness, and the strange sensation of hearing your own breathing.

Five patients were female, two male, ages 28 to 56. PET appeared after four to ten months of therapy. One patient improved with conservative management; six needed in-office injections to bulk up the tubal walls. The proposed mechanism is mundane: rapid loss of peritubal fat removes a soft-tissue cushion that normally keeps the tube collapsed.

Seven cases from one clinic is not an epidemic. It is, however, the first formal report of this association, and it's a reminder that very fast weight loss has anatomical consequences in places we don't usually monitor.

Not much, yet — and that's the honest answer. If you're already on a GLP-1 for weight or glycemic reasons, none of these papers argues for stopping. The cardiometabolic review, if anything, strengthens the case for staying on. The asthma data is interesting if you happen to sit in the steroid-dependent subgroup, but it's not a reason on its own to seek the drug. The ear side effect is rare enough that it shouldn't drive the decision, but specific enough that you'd want to recognize it.

The broader point is that GLP-1s are behaving the way most powerful drugs eventually do: revealing both upside and downside as the denominator of users grows. The optimization move isn't to chase every new signal. It's to stay current, work with a clinician who's doing the same, and let the evidence base mature before treating any single 2025 paper as a verdict.